Trial Profile

Safety, Tolerability, and Pharmacokinetics of Intravitreal Single Rising Doses and Multiple Doses of BI 771716 in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration (Open Label, Non-randomized)

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 23 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

05 Sep 2024 According to a Boehringer Ingelheim media release, the company has this study has met its primary safety endpoints. Charles C. Wykoff is principal investigator in this trial.
06 Jun 2024 Status changed from active, no longer recruiting to completed.
30 Apr 2024 According to a CDR Life media release, the company announced Fourth Milestone Achievement of the Phase 1 trial with BI 771716 in partnership with Boehringer Ingelheim for the treatment of Geographic Atrophy.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com